Avanos Medical (NYSE:AVNS) Updates FY 2025 Earnings Guidance

Avanos Medical (NYSE:AVNS) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 1.050-1.250 for the period, compared to the consensus EPS estimate of 1.670. The company issued revenue guidance of $665.0 million-$685.0 million, compared to the consensus revenue estimate of $713.1 million.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded Avanos Medical from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 3rd.

Avanos Medical Price Performance

Shares of AVNS traded up $0.25 during mid-day trading on Wednesday, hitting $15.81. The company’s stock had a trading volume of 565,431 shares, compared to its average volume of 539,626. The stock has a market capitalization of $726.67 million, a price-to-earnings ratio of 46.50 and a beta of 0.98. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.22 and a quick ratio of 1.46. The firm has a 50-day moving average price of $16.15 and a 200 day moving average price of $19.73. Avanos Medical has a fifty-two week low of $14.40 and a fifty-two week high of $25.36.

Avanos Medical (NYSE:AVNS) last announced its earnings results on Wednesday, February 26th. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.40 by $0.03. Avanos Medical had a return on equity of 4.70% and a net margin of 2.30%. On average, research analysts predict that Avanos Medical will post 1.32 EPS for the current fiscal year.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.